Business Wire

BACARDI-LIMITED

16.12.2020 08:02:14 CET | Business Wire | Press release

Share
‘Less Is More’: Bacardi Predicts 400% Growth in No and Low Alcohol in Next Four Years

Bacardi Limited, the world’s largest family-owned spirits company, is launching a new ‘mindful drinking’ campaign this January, designed to help retailers, bars and e-commerce partners tap into a sales opportunity worth a predicted $500m RSV by the end of 2024iii .

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201215006215/en/

Mindful drinking - the practice of being aware of why, how much and what alcohol we drink - is a cultural movement which has become incredibly popular this year. The concept covers everything from replacing alcohol with alcohol-free spirits, to enjoying longer, low alcohol drinks, as well as taking the time to ‘sip and savour’ cocktails made with the finest, natural ingredients.

This idea of moderation without settling for second-best continues to gain traction across the world, and nowhere more so than in Western Europe. The lockdowns and restrictions of 2020 have only accelerated its growth:

  • +30% and +25% more Google searches are for non-alcoholic beverages in the UK and Germany respectively, compared to this time last year
  • In both countries, Google searches for “Aperitivo” saw a dramatic rise from March 2020 as people began researching NoLo cocktails to enjoy at homeiv

Brenda Fiala, Global VP, Strategic Insights & Analytics for Bacardi , casts a light on this growing drinks trend: “What really stands out in our insights is just how huge mindful drinking has become in Western Europe this year (compared to last year). It is becoming the ‘NoLo capital of the world’. As lockdown impacted our lives and routines, not only did people begin to seek out lower ABV cocktails, they also began enjoying cocktails a little earlier than usual and began experimenting with longer drinks and alcohol-free options. That meant mindful drinking really took off and it’s here to stay.”

Over a third (36%) of consumers across the UK, France and Germany planning on enjoying cocktails more mindfully during Decemberv

  • Partipation in a ‘Dry-ish January’ is set to be at its highest ever – almost half (48%) of consumers surveyed in the UKvi and a quarter (24%) of those asked in Germany, plan to take partvii

With its successful portfolio of NoLo drinks, the family-owned sprits company has been ahead of the curve on the mindful drinking trend, and this new ‘Less is More’ campaign demonstrates an even bigger focus and investment in the category’s future. It will drive awareness of the company’s mindful drinking line-up of premium drinks, including recently launched MARTINI Non-Alcoholic Aperitivo, as well as MARTINI Fiero vermouth and ST-GERMAIN® elderflower liqueur.

Marine Rozenfeld, Innovation Development Lead for Bacardi for Western Europe, Australia & New Zealand , comments: “We know people are stepping up their cocktail game with premium spirits, putting quality over quantity, and at the same time, are intrigued by the explosion of new alcohol-free spirits available to choose from. Now it’s about taking them further on the journey of exploration. From MARTINI Non-Alcoholic cocktails , to longer drinks like the ST-GERMAIN Spritz and the MARTINI Fiero & Tonic, we want to help give people the tools and know-how they need to drink mindfully. Our message is very simple - ‘Less is More ’ - more taste, more experience.”

The new Bacardi marketing initiative has two key focuses – visibility and education – aiming to signpost “NoLo” options for cocktail-lovers, bartenders and store owners, in a way that’s both engaging and easy-to-understand.

Bacardi will be:

  • deploying menu cards and editable templates to bars
  • leaflets and stand-out POS displays in retail
  • launching dedicated ‘Less is More ’ Amazon gift stores in UK, Germany and Spain to inspire at-home bartenders with recipes and interactive content
  • using social media to drive awareness for MARTINI Non-Alcoholic Aperitivo in selected markets
  • hosting samplings across retail and when they can reopen, in bars

Bartenders are getting excited by the opportunities to create amazing mindful cocktails too. As Bacardi continues to support the bar industry through its #RaiseYourSpirits initiative, its education program on how to create cocktails for mindful drinkers, is another way in which the company is helping bar owners maximise sales by tapping into this trend once they reopen.

For those looking to drink mindfully during the festive season, to participate in Dry January or for gifting ideas for mindful drinkers, Bacardi has Gift Stores on Amazon in the UK, France, Germany, Spain and Italy where they can shop for fantastic NoLo premium spirits including a MARTINI Non-Alcoholic Aperitivo Vibrante and Floreale Dual Set (2 x 75cl).

NOTES TO EDITORS

Always drink responsibly
For the facts: Drinkaware.co.uk

About Bacardi

Bacardi Limited, the largest privately held spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi Limited brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka. Founded more than 158 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 7,000, operates production facilities in 11 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit www.bacardilimited.com or follow us on Twitter , LinkedIn or Instagram .

ALL MARKS APPEARING ON THE BACARDI GROUP PRODUCTS SHOWN OR MENTIONED ARE TRADEMARKS OF BACARDI & COMPANY LIMITED OR OF OTHER SUBSIDIARIES OF BACARDI LIMITED.
_____________________
i
Bacardi predicted value of the NoLo spirits category ($) in Western Europe by 2024, based on IWSR predictions. All channels.
ii Indicative results based on consumer research conducted in the UK, France and Germany. 50% UK participants, 34% French participants and 23.5% German participants said they plan to drinking more mindfully during the festive season
iii Bacardi predicted value of the NoLo spirits category ($) in Western Europe by 2024, based on IWSR predictions. All channels.
iv Independent Google trends data
v Indicative results based on consumer research conducted in the UK, France and Germany. 50% UK participants, 34% French participants and 23.5% German participants said they plan to drinking more mindfully during the festive season.
vi The research of 1,000 UK respondents aged 18-55 was conducted via Perspectus Global during October 2020.
vii In the period from 19-20.11.2020, the market and opinion research company Civey asked more than 3,800 people in Germany who drink alcohol about their consumption of alcohol during the pandemic, the Christmas holidays and the Dry January. 

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release

Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat

Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release

£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e

Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release

Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int

Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release

Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'

Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release

Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye